Thursday, April 23, 2009

BMS - Onglyza: three more months

U.S. regulators need more time to review the new diabetes drug Onglyza from AstraZeneca and Bristol-Myers Squibb.

The FDA has delayed a decision on whether the product should be approved by three months to July 30th.

No comments: